

## Bio sketch – Stefan Peukert

Dr. Peukert studied chemistry at the University of Freiburg (Germany), Cambridge University (UK) and Stanford University (USA). He obtained his PhD in organic chemistry from the University of Basel (Switzerland) in 1998 under the guidance of Prof. Bernd Giese working on mechanistic studies and synthetic applications of the radical-induced heterolytic bond cleavage. After postdoctoral research with Prof. Eric Jacobson at Harvard University on synthetic applications of solid-phase supported Co(salen) complexes he started his career in the pharmaceutical industry at Aventis (now Sanofi) in Frankfurt. For five years he worked as a medicinal chemist on cardiovascular programs, most notably on selective Kv1.5 inhibitors for the treatment of atrial fibrillation. In 2004 he joined Global Discovery Chemistry at the Novartis Institutes of Biomedical Research (Cambridge, USA), where he is currently leading a group in cardiovascular and metabolism chemistry. The research activities of his group include both program building and late stage lead optimization. During this tenure with Novartis he has been involved in programs for infectious disease, oncology, cardiovascular and diabetes resulting in multiple clinical candidates up to phase III trials. His scientific work has been documented in more than 50 publications and patent applications.